A high intensity vs. casual speed walking intervention to reverse frailty among older adults: a cluster randomized controlled trial.

PLoS OneSep 30, 2026 (epub)
Clinical ResearchGeriatrics

Margaret Danilovich, Daniel S Rubin, David E Conroy et al.

✦ AI-curated · Sources linked

In 30 seconds

This cluster-randomized controlled trial evaluated the effects of high-intensity walking (HIW) versus casual-speed walking (CSW) on frailty in 165 prefrail and frail adults aged ≥60 years. The study found that 69.6% of HIW participants improved in frailty category compared to 46.4% in the CSW group (OR = 2.91, p = 0.02), indicating HIW's superior effectiveness in reversing frailty.

Key findings

  • 69.6% of HIW participants improved in frailty category compared to 46.4% in CSW (OR = 2.91, p = 0.02).
  • HIW participants had a mean gait speed increase of 0.08 m/s (p = 0.036).
  • HIW participants walked 48.99 meters further in the 6MWT compared to CSW (p = 0.0088).
  • Mean HRmax was significantly higher in HIW (71%) than in CSW (59%, p < 0.001).

Why it matters

Understanding the impact of walking intensity on frailty can guide interventions aimed at improving mobility and quality of life in older adults, potentially reducing disability and healthcare costs associated with frailty.

Source

PubMed · PMID 42814673

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.